Back to results
US 6,787,323 B2Granted
VEGF responsive cell-based assay for determining VEGF bioactivity
AssigneePfizer Inc.
InventorsBrian Lee Batley, Tawny Kay Dahring, Sotirios K. Karathanasis, Robert Lee Panek, Ye Edward Tian
Life of this patent
Estimating the term…
Abstract
A VEGF responsive cell-based assay for determining VEGF bioactivity is disclosed. The assay utilizes established signal transduction pathways in a method for determining VEGF bioactivity in a sample.
Claims2
A method for determining vascular endothelial growth factor (VEGF) activity in a sample, said method comprising the steps of:
- a) contacting a sample to be assayed for VEGF activity with a stable HeLa cell line wherein the stable HeLa cell line comprises:
- 1) a reporter vector having;
- an expressible reporter element and a DNA binding site disposed adjacent thereto and,
- 2) a chimeric transactivator vector comprising
- a gene encoding a phosphorylatable protein that can be phosphorylated by MAPK and a DNA binding domain which specifically binds to the DNA binding site, and
- 3) an expression vector encoding a gene for a VEGF receptor;
- and
- b) detecting expression of the reporter element, wherein expression of the reporter element indicates VEGF activity wherein the sample comprises cells, tissue, tissue extracts or combinations thereof.
5 more elements
A method for determining vascular endothelial growth factor (VEGF) activity in a sample, said method comprising the steps of:
- a) contacting a sample to be assayed for VEGF activity with a stable HeLa cell line wherein the stable HeLa cell line comprises:
- 1) a reporter vector having;
- an expressible reporter element and a DNA binding site disposed adjacent thereto and,
- 2) a chimeric transactivator vector comprising
- a gene encoding a phosphorylatable protein that can be phosphorylated by MAPK and a DNA binding domain which specifically binds to the DNA binding site, and
- 3) an expression vector encoding a gene for a VEGF receptor;
- and
- b) detecting expression of the reporter element, wherein expression of the reporter element indicates VEGF activity, and wherein the contacting step comprises incubating the sample with the stable HeLa cell line for a period of time ranging from approximately 10 hours to approximately 20 hours.
5 more elements
Dependencies are inferred from the claim text.